¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Host Cell Factor C1"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
  • cell swelling
    ¼¼Æ÷Á¾Ã¢
  • cell-associated antibody
    ¼¼Æ÷¿¬°üÇ×ü
  • cell-bound antibody
    ¼¼Æ÷°áÇÕÇ×ü
  • cell-fixed antibody
    ¼¼Æ÷°áÇÕÇ×ü
  • cell-mediated cytolysis
    ¼¼Æ÷¸Å°³¼¼Æ÷¿ëÇØ
  • cell-mediated cytotoxicity
    ¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • cell-mediated hypersensitivity
    ¼¼Æ÷¸Å°³°ú¹Î¼º
  • cell-mediated immunity
    ¼¼Æ÷¸Å°³¸é¿ª
  • cell-mediated reaction
    ¼¼Æ÷¸Å°³¹ÝÀÀ
  • cell-mediated response
    ¼¼Æ÷¸Å°³¹ÝÀÀ
  • centroacinar cell
    »ù²Ê¸®Á߽ɼ¼Æ÷, Á߽ɼ±¹æ¼¼Æ÷
  • chief cell
    À¸¶ä¼¼Æ÷
  • chromaffin cell
    Å©·Òģȭ¼¼Æ÷, ģũ·Ò¼¼Æ÷
  • chromophilic cell
    »ö¼Òµê¼¼Æ÷, È£»ö¼Ò¼¼Æ÷
  • chromophobic cell
    »ö¼Ò¾Èµê¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
  • centroacinar cell
    »ù²Ê¸®Á߽ɼ¼Æ÷
  • chief cell
    À¸¶ä¼¼Æ÷
  • Chinese hamster ovary cell
    Áß±¹ºñ´ÜÅÐÁã³­¼Ò¼¼Æ÷
  • chromaffin cell
    ģũ·Ò¼¼Æ÷, Å©·Òģȭ¼¼Æ÷
  • chromophilic cell
    »ö¼Òµë¼¼Æ÷, È£»ö¼Ò¼¼Æ÷
  • chromophobic cell
    »ö¼Ò¾Èµë¼¼Æ÷
  • ciliated cell
    ¼¶¸ð¼¼Æ÷, ÀÜÅм¼Æ÷
  • clear cell
    Åõ¸í¼¼Æ÷
  • clear cell carcinoma
    Åõ¸í¼¼Æ÷¾ÏÁ¾
  • clear cell hidradenoma
    Åõ¸í¼¼Æ÷¶¡»ùÁ¾
  • clear cell sarcoma
    Åõ¸í¼¼Æ÷À°Á¾
  • columnar cell
    ¿øÁÖ¼¼Æ÷
  • columnar absorptive cell
    ±âµÕÈíÂø¼¼Æ÷
  • committed cell
    ¾ô¸Ç¼¼Æ÷, ¼öÀÓ¼¼Æ÷
  • complex cell
    º¹ÇÕ¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
  • apical cell
    Á¤(´Ü)¼¼Æ÷(ð¢Ó®á¬øà)
  • argentaffin chromaffin cell
    Å©·Òģȭ¼º ¼¼Æ÷
  • argyrophil(e) cell
    ÀºÄ£È­¼º ¼¼Æ÷(ëÞöÑûúàõá¬øà)
  • arsenical basal cell carcinoma
    ºñ¼Ò¼º(Ý÷áÈàõ) ±âÀú¼¼Æ÷¾Ï
  • arteritis,giant cell of aorta
    ´ëµ¿¸Æ(ÓÞÔÑØæ)ÀÇ °Å¼¼Æ÷¼º(ËÝá¬øààõ)
  • free cell
    ÀÚÀ¯¼¼Æ÷(í»ë¦á¬øà).
  • functional cell
    ±â´É¼¼Æ÷(ѦÒöá¬øà).
  • funicular cell
    ÁÙ¼¼Æ÷, »è¼¼Æ÷(ßãá¬øà).
  • fusiform cell
    ¹æÃß¼¼Æ÷
  • fusiform endothelial cell
    ¹æÃß³»ÇǼ¼Æ÷
  • fusiform myoepithelial cell
    ¹æÃßÇü ±Ù»óÇÇ ¼¼Æ÷
  • fusiform myoepithelial cell
    ¹æÃß±ÙÀ°»óÇǼ¼Æ÷
  • fusion, cell
    ¼¼Æ÷À¶ÇÕ
  • gangliocyte =ganglion cell
    ½Å°æÀý¼¼Æ÷(¡­á¬øà).
  • ganglion cell =gangliocyte
    ½Å°æÀý¼¼Æ÷(¡­á¬øà).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
  • insulin-like growth factor
    Àν¶¸°À¯»ç¼ºÀåÀÎÀÚ
  • intensity factor
    °­µµÀÎÀÚ
  • intrinsic factor
    ³»ÀμºÀÎÀÚ, ³»Àμº¿ä¼Ò, °íÀ¯ÀÎÀÚ
  • intrinsic factor
    ³»ÀÎÀÚ
  • intrinsic factor =IF
    ³»ÀÎÀÚ(Ò®ì×í­).
  • intrinsic factor(if)
    ³»ÀÎÀÚ(Ò®ì×í­)
  • islet-activation factor
    ¶û°Ô¸£Çѽº»ù Ȱ¼ºÀÎÀÚ, ¹éÀÏÇØ±Õµ¶¼Ò
  • isodose shift factor
    µî¼±·®À̵¿°è¼ö
  • kerma factor
    Ä¿¸¶ °è¼ö
  • ketogenic factor
    ÄÉÅæÃ¼Çü¼ºÀÎÀÚ(¡­ô÷û¡à÷ì×í­).
  • labile factor
    ºÒ¾ÈÁ¤ÀÎÀÚ, ºÒ¾ÈÁ¤¿ä¼Ò.
  • lactogenic factor
    ÃÖÀ¯ÀÎÀÚ(¡­ì×í­).
  • lactogenic factor
    À¯ÁóºÐºñÀ¯µµÀÎÀÚ(¡­ì×í­).
  • leucocyte inhibition factor
    ¹éÇ÷±¸¾ïÁ¦ÀÎÀÚ.
  • leucocytosis promoting factor
    ¹éÇ÷±¸Áõ°¡ÀÎÀÚ, ¹éÇ÷±¸Áõ´ÙÁõÃËÁøÀÎÀÚ.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
  • resistance factor
    ÀúÇ× ÀÎÀÚ(ì×í­)
  • resistance-transfer factor
    ÀúÇ×ÀüÀÌ ÀÎÀÚ(ï®ì¹ì×í­)
  • R factor
    R ÀÎÀÚ(ì×í­)
  • Rhesus factor
    ·¹¼­½º ÀÎÀÚ(ì×í­)
  • rheumatoid factor
    ·ù¸¶ÅäÀ̵å ÀÎÀÚ
  • Rh factor
    Rh ÀÎÀÚ
  • rho factor
    rho ÀÎÀÚ
  • ribosome dissociating factor
    ¶óÀ̺¸¼Ø ÇØ¸®ÀÎÀÚ(ú°×îì×í­)
  • separation factor
    ºÐ¸®ÀÎÀÚ(ÝÂ×îì×í­)
  • serum prothrombin converting factor
    Ç÷û(úìôè) ÇÁ·ÎÆ®·Òºó ÀüȯÀÎÀÚ(ï®üµì×í­)
  • serum sulfation factor
    Ç÷û À¯È²È­ÀÎÀÚ(úìôè×¼üÜûùì×í­)
  • serum thymic factor
    Ç÷û °©»ó¼±ÀÎÀÚ(úìôèË£ßÒàÍì×í­)
  • sex factor
    ¼ºÀÎÀÚ(àõì×í­)
  • shape factor
    ¸ð¾çÀÎÀÚ(Ù¼åÆì×í­)
  • sigma factor
    ½Ã±×¸¶ÀÎÀÚ(ì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 18
DRF Daily Rating Form; daily replacement factor; Deafness Research Foundation; dose reduction factor
EDF eosinophil differentiation factor; erythroid differentiation factor; extradural fluid
EIF erythrocyte initiation factor; eukaryotic initiation factor
FF degree of fineness of abrasive particles; fat-free; father factor; fecal frequency; fertility factor...
GF gastric fistula; gastric fluid; germ-free; glass factor; glomerular filtration; gluten-free; grandfa...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 18
ATLV Adult T cell leukemia virus
ATLL Adult T cell leukemia/lymphoma
ATLL Adult T cell lymphoma/leukaemia
ATLA Adult T-cell leukemia-associated antigen
AEC Airway epithelial cell
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • clear cell hidradenoma
    Åõ¸í ¼¼Æ÷ ÇѼ±Á¾
  • clear cell sarcoma
    Åõ¸í ¼¼Æ÷ À°Á¾
  • cleared cell
    Åõ¸í ¼¼Æ÷
  • columnar cell carcinoma
    ¿øÁÖ ¼¼Æ÷ ¾ÏÁ¾
  • columnar epithelial cell
    ¿øÁÖ »óÇÇ ¼¼Æ÷
  • columns of cartilage cell
    ¿¬°ñ ¼¼Æ÷ ±âµÕ, ¿¬°ñ ¼¼Æ÷ÁÖ
  • committed cell
    À§Å¹ ¼¼Æ÷
    ¾î¶² ƯÁ¤ÇÑ Ç׿ø °áÁ¤±º¿¡ ´ëÇØ¼­ ƯÀÌÀûÀÎ Ç×ü¸¦ »ý»êÇϵµ·Ï À§Å¹µÈ ¼¼Æ÷. À§Å¹ ¼¼Æ÷¿¡´Â Ç׿øÀÌ Á¢Ã˵Ǿú´ø ÀûÀÌ ÀÖ´Â ¼¼Æ÷, ±â¾ï¼¼Æ÷, ¹× Ç×ü»ý»ê ¼¼Æ÷ µîÀÌ Æ÷ÇԵȴÙ.
  • companion cell
    µ¿¹Ý ¼¼Æ÷
  • cone cell
    ¿ø»Ô ¼¼Æ÷, Ãß»óü ¼¼Æ÷, ¿øÃß ¼¼Æ÷
    ôÃßµ¿¹°ÀÇ ¸Á¸·ÀÇ °¡Àå ¾ÈÂÊ¿¡ ÀÖ´Â ½Ã¼¼Æ÷ÀÇ ÀÏÁ¾. Ãßü ¼¼Æ÷, Ãß»óü ¼¼Æ÷¶ó°íµµ ÇÑ´Ù. ½Ã¼¼Æ÷´Â ±× ÇüÅÂ¿Í ±â´É»ó¿¡ µû¶ó ¿øÃß ¼¼Æ÷¿Í °£»ó ¼¼Æ÷ÀÇ 2Á¾À¸·Î ±¸º°µÈ´Ù. ¿øÃß ¼¼Æ÷´Â ºñ±³Àû ¹àÀº °÷¿¡¼­ ¹°Ã¼¸¦ º¸´Â ÀÏ, »öÀ» ½Äº°
  • congenital granular cell epulis
    ¼±ÃµÀû °ú¸³¼¼Æ÷¼º Ä¡ÀºÁ¾
  • cornified epithelial cell
    °¢È­ »óÇÇ ¼¼Æ÷
  • cortical cell
    ÇÇÁú ¼¼Æ÷
  • crystal cell
    °áÁ¤ ¼¼Æ÷
    ³»ºÎ¿¡ °¢Á¾ °áÁ¤À» ÇÔÀ¯ÇÏ´Â ¼¼Æ÷. ºÐºñ ¼¼Æ÷ÀÇ ÀÏÁ¾À¸·Î, º¸Åë ÁÖÀ§ÀÇ ¼¼Æ÷¿Í ¸ð¾çÀÌ ¾à°£ ´Ù¸£´Ù. Á¤¹æÁ¤°è ¶Ç´Â ´Ü»çÁ¤°è·Î µÈ Å« ¿Á»ì»ê Ä®½· °áÁ¤À» º£°í´Ï¾Æ¼Ó µî ½Ä¹°Á¶Á÷ ³»¿¡¼­ ÈçÈ÷ º¼ ¼ö ÀÖ´Ù. ¶§·Î´Â ¼ÒÇüÀÇ °áÁ¤ÀÌ ´Ù¼ö ±ºÁýÇÏ¿© °áÁ¤»ç°¡ µÇ°Å³ª ħ»ó °áÁ¤ÀÌ ´Ù¼ö ÆòÇàÀ¸·Î ¹è¿­µÇ¾î °áÁ¤ ¼ÓÀÌ µÈ´Ù
  • cutaneous B cell lymphoma
    ÇǺΠB ¼¼Æ÷ ¸²ÇÁÁ¾
  • cylindrical cell
    ¿øÁÖÇü ¼¼Æ÷, ¿øÁÖ»ó ¼¼Æ÷
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 18
thyrotoxic complement-fixation factor A form of thyrotoxin; an antigen found most readily in thyroid tissue from thyrotoxic individuals; known to be chemically and immunologically distinct from thyroglobulin, and fixes complement when combined with antibody related to the gamma-globulin fraction of serum. With the exception of extremely small concentrations, the antigen is rarely found in normal glands or in diseased glands that are not associated with thyrotoxicosis; it is probably an intracellular substance (possibly a constituent of the "microsomal fraction"), and does not contain iodine in significant quantity. Not related to the complement-fixation reaction occurring with serum in Hashimoto's disease, in which the antigen is thyroglobulin.
(05 Mar 2000)
thyrotropin-releasing factor Former name for thyrotropin-releasing hormone.
(05 Mar 2000)
tissue factor <cell biology> Integral membrane glycoprotein of around 250 residues, that initiates blood clotting after binding factors VII or VIIa.
(18 Nov 1997)
tissue weighting factor In radiation protection, a factor weighting the equivalent dose in a particular tissue or organ in terms of its relative contribution to the total deleterious effects resulting from uniform irradiation of the whole body.
See: effective dose.
(05 Mar 2000)
elongation factor <biochemistry> Peptidyltransferase components of ribosomes that catalyse formation of the acyl bond between the incoming amino acid residue and the peptide chain.
There are three classes of elongation factor: EF1_ (EF Tu in prokaryotes) binds GTP and aminoacyl tRNA, delivering it to the A site of ribosomes. EF 1_ (EF Ts) helps in regeneration of GTP EF 1_. EF 2 (EF G) binds GTP and peptidyl tRNA and translocates it from the A site to the P site. Diptheria toxin inhibits protein synthesis in eukaryotes by adding an ADP ribosyl group to a modified histidine residue (dipthamide) in elongation factor II.
(18 Nov 1997)
transcription factor <molecular biology> Protein required for recognition by RNA polymerases of specific stimulatory sequences in eukaryotic genes.
Several are known that activate transcription by RNA polymerase II when bound to upstream promoters.
Transcription of the 5S RNA gene in Xenopus by RNA polymerase III is dependent on a 40 kD protein TFIIIA that binds to a regulatory site in the centre of the gene and was the first protein found to exhibit the metal binding domains known as zinc fingers.
(17 Mar 1998)
transcription factor ap-1 A multiprotein complex composed of the products of c-jun and c-fos proto-oncogenes. These proteins must dimerise in order to bind to the ap-1 recognition site, also known as the tpa-responsive element (tre). Ap-1 controls both basal and inducible transcription of several genes.
(12 Dec 1998)
transcription factor, sp1 Promoter-specific RNA polymerase II transcription factor that binds to the gc box, one of the upstream promoter elements (upe) in mammalian cells. The binding of sp1 is necessary to initiate transcription in the promoters of a variety of cellular and viral genes including c-ha-ras and HIV.
(12 Dec 1998)
transfer factor A dialysable factor obtained from sensitised T-cells by freezing and thawing, that may possibly immunopotentiate animals.The transfer of specific immunity from one animal to another has been claimed.
(18 Nov 1997)
transforming factor The DNA responsible for bacterial transformation.
(05 Mar 2000)
transforming growth factor <growth factor> Proteins secreted by transformed cells that can stimulate growth of normal cells.
Unfortunate misnomer, since they induce aspects of transformed phenotype, such as growth in semi solid agar, but do not actually transform.
Transforming growth factor alpha, 50 amino acid polypeptide originally isolated from viral transformed rodent cells, contains EGF like domain and binds to EGF receptor. Stimulates growth of microvascular endothelial cells, i.e. Is angiogenic.
Transforming growth factor beta a homodimer of two 112 chains, polypeptide is secreted by many different cell types, stimulates wound healing but in vitro is also a growth inhibitor for certain cell types. The transforming growth factor family includes many of the bone morphogenetic proteins.
Acronym: TGF
(18 Nov 1997)
transforming growth factor alpha Factor isolated in a variety of tissues including epithelium, and maternal decidua. It is closely related to epidermal growth factor (epidermal growth factor-urogasterone) and binds to the egf receptor. Tgf-alpha acts synergistically with tgf-beta in inducing phenotypic transformation, but its physiological role is unknown.
(12 Dec 1998)
transforming growth factor beta Factor synthesised in a wide variety of tissues including platelets, placenta, and both normal and transformed cell lines. It acts synergistically with tgf-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. Tgf-beta also has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. There are at least three forms of tgf-beta: tgf-beta1, tgf-beta2, and tgf-beta1.2. The latter is a heterodimer made up of both tgf-beta1 and tgf-beta2.
(12 Dec 1998)
transmethylation factor <biochemistry> Esterified in the head group of phospholipids (phosphatidylcholine and sphingomyelin) and in the neurotransmitter acetylcholine. Otherwise a biological source of methyl groups.
(18 Nov 1997)
endothelial relaxing factor A molecule functioning as a neurotransmitter and produced by activated macrophages. It is capable of killing tumour cells, parasites, and intracellular bacteria.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 18
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 18
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 18
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 18
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 18
ÅëÇÕ°Ë»ö ¿Ï·á